Lifecore Biomedical Inc. (LFCR)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $243.36M
Last updated: Nov 17, 2026 at 11:03 AM ET
Lifecore Biomedical Inc. (LFCR) Financials: Revenue, Profit and Cash Flow
Lifecore Biomedical reported revenue of $128.87M for the fiscal year ended May 31, 2025, up 0.5% from the year before. That year, net income was -$38.72M with a net margin of -30.0%, operating cash flow was -$206.00K and free cash flow was -$13.62M. The quarter ended Sep 30, 2026 had revenue of $25.32M and net income of -$40.08M.
Revenue and Margins
The operating margin was -13.4% in the fiscal year ended May 2025. Over the 9 years to May 2025, revenue fell from $476.92M, a compound annual decline of 13.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| May 2025 | $128.87M | +0.5% | 31.3% | -13.4% | -30.0% |
| May 2024 | $128.26M | +24.2% | 32.6% | -6.9% | 9.4% |
| May 2023 | $103.27M | -7.2% | 27.1% | -21.1% | -96.4% |
| May 2022 | $111.27M | +10.3% | 35.1% | -10.6% | -104.9% |
| May 2021 | $100.87M | -37.0% | 38.6% | -8.7% | -32.0% |
| May 2020 | $160.07M | -71.3% | 24.6% | -16.2% | -23.9% |
| May 2019 | $557.56M | +6.4% | 14.5% | 1.0% | 0.1% |
| May 2018 | $524.23M | +11.6% | 14.9% | 2.6% | 4.8% |
| May 2017 | $469.78M | -1.5% | 16.9% | 3.1% | 2.3% |
| May 2016 | $476.92M | N/A | 14.0% | -4.3% | -2.4% |
Income Statement
In the fiscal year ended May 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 | May 2019 | May 2018 | May 2017 | May 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $128.87M | $128.26M | $103.27M | $111.27M | $100.87M | $160.07M | $557.56M | $524.23M | $469.78M | $476.92M |
| Cost of revenue | $88.57M | $86.41M | $75.28M | $72.20M | $61.94M | $120.68M | $476.56M | $445.89M | $390.56M | $410.14M |
| Gross profit | $40.30M | $41.85M | $27.98M | $39.07M | $38.94M | $39.39M | $81.00M | $78.34M | $79.21M | $66.78M |
| Research and development | $8.26M | $8.57M | $8.74M | $7.84M | $6.68M | $7.58M | $11.47M | $12.80M | $9.47M | $7.23M |
| Operating income | -$17.25M | -$8.84M | -$21.80M | -$11.79M | -$8.82M | -$25.88M | $5.47M | $13.59M | $14.67M | -$20.63M |
| Net income | -$38.72M | $12.01M | -$99.56M | -$116.72M | -$32.29M | -$38.19M | $411.00K | $24.92M | $10.68M | -$11.45M |
| EBITDA | -$8.81M | $35.56M | -$9.43M | $12.84M | $75.00K | -$7.23M | $22.30M | $28.90M | $26.25M | -$10.03M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Feb 2026 | Nov 2025 | Sep 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.32M | $34.17M | $23.19M | $23.19M | $34.17M | $31.11M | $23.19M | $36.44M | $35.15M | $32.56M | $24.70M | $37.88M |
| Gross profit | $6.83M | $12.07M | $4.46M | $4.46M | $12.07M | $7.79M | $4.46M | $13.98M | $9.85M | $11.08M | $5.39M | $17.27M |
| Operating income | -$894.00K | $2.57M | -$4.67M | -$4.67M | $2.57M | -$3.07M | -$4.67M | $5.33M | -$9.03M | -$1.96M | -$11.58M | $2.15M |
| Net income | -$40.08M | -$6.16M | -$14.98M | -$14.98M | -$6.16M | -$9.99M | -$14.98M | -$1.15M | -$14.77M | -$6.57M | -$16.23M | -$7.08M |
Balance Sheet
As of May 2026, total debt of $136.91M exceeded cash and equivalents by $119.44M. Shareholder equity was negative, at -$14.20M, as total liabilities of $246.38M exceeded total assets of $232.18M.
Annual
| Line item | May 2026 | Dec 2025 | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 | May 2019 | May 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $232.18M | $232.18M | $232.18M | $253.96M | $253.54M | $274.70M | $501.88M | $541.31M | $519.09M | $404.70M |
| Current assets | $82.29M | $82.29M | $82.29M | $81.03M | $93.88M | $116.67M | $145.30M | $157.11M | $133.04M | $97.06M |
| Cash and equivalents | $17.47M | $17.47M | $17.47M | $8.46M | $19.09M | $991.00K | $763.00K | $360.00K | $1.08M | $2.90M |
| Total liabilities | $246.38M | $198.12M | $198.12M | $200.06M | $218.46M | $186.88M | $299.94M | $310.27M | $248.95M | $152.14M |
| Short-term debt | $1.33M | N/A | $3.82M | $4.91M | $580.00K | $138.18M | $29.00M | $88.95M | $61.79M | $31.94M |
| Long-term debt | $135.59M | $141.28M | $141.28M | $123.72M | $101.06M | $0 | $164.90M | $101.36M | $87.19M | $37.36M |
| Shareholder equity | -$14.20M | -$14.20M | -$14.20M | $11.31M | -$4.23M | $87.82M | $201.95M | $231.04M | $270.14M | $252.56M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | May 2026 | Mar 2026 | Feb 2026 | Dec 2025 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $228.30M | $229.50M | $232.18M | $225.50M | $225.50M | $232.18M | $229.50M | $225.50M | $239.34M | $237.69M | $255.39M | $246.82M |
| Total liabilities | $250.58M | $213.41M | $246.38M | $204.72M | $204.72M | $198.12M | $213.41M | $204.72M | $238.01M | $190.27M | $195.63M | $207.32M |
| Cash and equivalents | $23.04M | $17.24M | $17.47M | $20.80M | $20.80M | $17.47M | $17.24M | $20.80M | $8.27M | $5.42M | $9.46M | $5.52M |
| Shareholder equity | -$73.40M | -$34.09M | -$14.20M | -$28.44M | $20.78M | -$14.20M | -$34.09M | -$28.44M | $1.34M | $2.23M | $15.45M | -$3.94M |
Cash Flow
Operating cash flow was negative in the fiscal year ended May 2025.
Annual
| Line item | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 | May 2019 | May 2018 | May 2017 | May 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$206.00K | $257.00K | -$17.44M | -$22.59M | $16.47M | -$17.04M | $16.02M | $19.78M | $29.84M | $20.76M |
| Capital expenditures | $13.41M | $18.39M | $21.48M | $29.94M | $25.22M | $26.69M | $44.73M | $33.59M | $23.00M | $39.70M |
| Free cash flow | -$13.62M | -$18.14M | -$38.92M | -$52.53M | -$8.75M | -$43.73M | -$28.71M | -$13.81M | $6.83M | -$18.93M |
| Dividends paid | N/A | $3.08M | $274.00K | N/A | N/A | $212.00K | $700.00K | $115.00K | $166.00K | $248.00K |
| Investing cash flow | -$6.42M | -$18.39M | -$4.81M | $79.96M | -$12.31M | -$23.89M | -$96.80M | -$35.59M | -$25.42M | -$40.42M |
| Financing cash flow | $6.42M | $7.51M | $39.70M | -$57.02M | -$3.42M | $40.02M | $79.03M | $13.29M | -$8.80M | $15.42M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Feb 2026 | Nov 2025 | Sep 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $6.95M | -$2.19M | $4.70M | $4.70M | -$2.19M | $5.96M | $4.70M | $7.16M | $1.20M | $7.16M | -$613.00K | $8.72M |
| Capital expenditures | $912.00K | $513.00K | $1.12M | $1.12M | $513.00K | $2.24M | $1.12M | $4.13M | $5.46M | $4.13M | $3.42M | $2.71M |
| Free cash flow | $6.03M | -$2.70M | $3.58M | $3.58M | -$2.70M | $3.72M | $3.58M | $3.03M | -$4.26M | $3.03M | -$4.04M | $6.00M |
Frequently Asked Questions About LFCR
What is Lifecore Biomedical's annual revenue?
Lifecore Biomedical reported revenue of $128.87M for the fiscal year ended May 31, 2025.
How fast is Lifecore Biomedical's revenue growing?
Revenue was up 0.5% for the fiscal year ended May 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.0%.
Is Lifecore Biomedical profitable?
No. Lifecore Biomedical reported net income of -$38.72M for the fiscal year ended May 31, 2025, with a net margin of -30.0%.
How much free cash flow does LFCR generate?
For the fiscal year ended May 31, 2025, operating cash flow of -$206.00K minus capital expenditures of $13.41M produced free cash flow of -$13.62M.
How much debt does Lifecore Biomedical have?
The balance sheet dated May 31, 2026 reported long-term debt of $135.59M, short-term debt of $1.33M and cash and equivalents of $17.47M.
LFCR pages: Overview, Earnings, Forecast, Financials, Competitors